Market News

Latest financial and economic news and analysis

Zacks Investment Research News Agency
11 hours agoZacks Investment Research
Stocks Medium Importance Neutral
Can Higher Occupancy Help Brookdale Senior Narrow Q2 Losses?

Can Higher Occupancy Help Brookdale Senior Narrow Q2 Losses?

Brookdale Senior Living Inc. BKD is set to report second-quarter 2026 results on Aug. 10, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter's earnings is currently pegged at a loss of 4 cents per share, indicating a year-over-year improvement of 77.8%.

Related Symbols 1
BKD BKD
Source: Zacks Investment Research
Visit Source
Comment
Zacks Investment Research News Agency
11 hours agoZacks Investment Research
Stocks Medium Importance Neutral
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?

Is MEDP Worth Buying as Growth Collides With a Premium Valuation?

Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

Related Symbols 1
MEDP MEDP
Source: Zacks Investment Research
Visit Source
Comment
GlobeNewsWire News Agency
11 hours agoGlobeNewsWire
Stocks Medium Importance Neutral
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ADMA

MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ADMA

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), have until this Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v.

Related Symbols 1
ADMA ADMA
Source: GlobeNewsWire
Visit Source
Comment